Clin J Am Soc Nephrol. 2010 May;5(5):744-5. doi: 10.2215/CJN.02610310. Epub 2010 May 6.
In its program END THE WAIT, the National Kidney Foundation (NKF) outlined four comprehensive strategies to achieve the goal that within 10 years, every individual on the US waiting list will receive a transplant within 1 year of listing. Lifetime immunosuppressive coverage is a critical piece of the foundation of this program. Events in 2009 that were dedicated toward achieving a lifetime immunosuppressive benefit were complicated by legislative challenges and a dynamic that placed oral medications in the ESRD bundling proposal in direct conflict with the potential for the lifetime immunosuppressive benefit. In line with its mission, the NKF could not sacrifice one kidney patient constituency for another. Successful patient-centered organizations stay consistent with their mission. The NKF had to weigh the risk of postponing a long-sought goal and its relationships with other organizations with standards of patient safety and equitable and efficient patient care. In a perfect world, we never have to make such choices. In the real world, we can use such choices to forge new ways and dialogue to achieve better health care for all patients affected by kidney disease.
在其 END THE WAIT 项目中,美国国家肾脏基金会 (NKF) 概述了四项全面战略,以实现这一目标,即在 10 年内,每个列入美国候补名单的人在列入候补名单后的一年内都将接受移植。终身免疫抑制覆盖是该计划的重要组成部分。2009 年,为实现终身免疫抑制获益而开展的活动受到立法挑战的影响,口服药物被纳入 ESRD 捆绑提案,这与终身免疫抑制获益的潜力直接冲突。为了实现其使命,NKF不能为了另一个患者群体而牺牲一个肾脏患者群体。成功的以患者为中心的组织始终坚持其使命。NKF 不得不权衡推迟长期寻求的目标的风险及其与其他组织的关系,以及患者安全、公平和高效的患者护理标准。在理想的世界中,我们不必做出这样的选择。在现实世界中,我们可以利用这些选择来开辟新的途径和对话,为所有受肾脏疾病影响的患者提供更好的医疗保健。